Contents
Foreword
About the report
Spotlight on Medicon Valley
Medicon Valley biopharma activity
Drug development
Clinical trial trends
Deal-making overview
European life science cluster comparison
Faces behind the innovation in Medicon Valley
Methodology
There is no doubt that the significance and impact of the life science sector in both Denmark and Sweden has been on the rise for several years and is still increasing in terms of exports, tax revenue, attractive jobs, etc.
Our cross-border region, Medicon Valley, is the largest life science region in the European Union in terms of number of jobs, but of course, we are also interested in being the leading in so many other ways.
On a daily basis, we see the value of joining forces in our cross-border Swedish-Danish life science region. Even if we are the largest region in the EU, we are just a dot on the world map. However, through collaboration and joining forces bi-nationally, in the EU and globally, we can increase our competitiveness by strengthening and creating new strongholds, achieving a greater impact and better ranking on world-class research, innovation, and making Medicon Valley an attractive hub for life science researchers, entrepreneurs, companies and investors.
Medicon Valley Alliance being a triple-helix, member-driven life science organisation with mission of strengthening the eco-system in Medicon Valley through networks, events, analysis, promotion and strategic projects, we are happy to present this brand new analysis and benchmarking of our region towards other prominent life science regions in Europe – displaying promises of an even brigther future for the life science sector.
Enjoy the read and kind regards
Anette Steenberg CEO – Medicon Valley Alliance
In close collaboration with Citeline, who has conducted the analysis, we have decided to zoom in on:
Drug development pipelines
Clinical trials conducted
Investment
Partnering statistics
Combining it with a benchmark comparison with other leading European life science clusters:
Pipeline size
Number of companies actively developing products
Ongoing and planned number of trials
Number of financing rounds
Key findings of Medicon Valley are:
An attractive maturing pipeline and biggest ever
A diversified and balanced pipeline
Metabolic/Endocrinology pushes aside oncology as the dominant disease area in trials
A flourish start-up scence
Investment has bounced back strongly in 2023, despite the continued global downturn within biotech
13 partnerships signed Q1+2, matching previous years, however, with values of a fourfold increase on 2021+22
Medicon Valley ranks #1 of life sciences clusters in the EU on several account